Transpire Bio's ANDA for Generic High-Strength Trelegy® Ellipta® Accepted for Filing by the U.S. FDA
SUNRISE, Fla., May 11, 2026 /PRNewswire/ -- Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company developing inhaled therapeutics for pulmonary and systemic diseases, today ...
Trelegy Ellipta is a maintenance treatment for patients with asthma and COPD. "The FDA's acceptance of our ANDA filing for the substitutable generic version of high-strength Trelegy Ellipta is another ...
Medicare Part D prescription drug plans may cover Trelegy Ellipta inhalers. Out-of-pocket costs can vary by plan and insurer, but you may only have to pay a 25% ...
Transpire Bio Inc., an integrated clinical- stage biopharmaceutical company developing inhaled therapeutics for pulmonary and systemic diseases, announces that its abbreviated new drug application ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results